Tyrosine kinase inhibitorFDA-approvedFirst-line
Ibrutinib
How it works
Blocks the Bruton's tyrosine kinase (BTK) enzyme, which is involved in B-cell receptor signaling and cancer growth.
Cancer types
Leukemia— All patients
Breast Cancer— All patients
Efficacy
In clinical trials, around 90% of patients with mantle cell lymphoma or Waldenström's macroglobulinemia achieved an objective response, with a median progression-free survival of approximately 2 years.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Treating Older Adults with Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-3 | — | Source → |
| Customizing Ibrutinib Treatment for Untreated Chronic Lymphocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Leukemia | phase-1 | — | Source → |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Ibrutinib Therapy Linked to Atrial Fibrillation in CLL Patients | Leukemia | observational | — | Source → |
| Combining Ianalumab with Ibrutinib Improves CLL Outcomes | Leukemia | preclinical | 38.5% of patients achieved a complete response or complete response with incomplete marrow recovery at cycle 9. | Source → |
| Pirtobrutinib Shows Promise in Treating Chronic Lymphocytic Leukemia | Leukemia | phase-3 | The overall response rate was 87.0% with pirtobrutinib versus 78.5% with ibrutinib. | Source → |
| Combination Therapy Fails to Improve CLL Response, but Activates CD8 T Cells | Leukemia | phase-2 | There was 1 complete response and 9 partial responses in 10 patients evaluable for response. | Source → |
| Optimizing Ibrutinib Doses for Chronic Lymphocytic Leukemia | Leukemia | phase-1/2 | Dose reductions based on response depth or toxicity preserved comparable response rates and progression-free survival to standard dosing. | Source → |
| Researchers Test New Skin Cancer Treatment Using Tiny Lipid Carriers | Melanoma | lab-study | — | Source → |
| Ibrutinib Treatment Outcomes in High-Risk CLL/SLL Patients | Leukemia | observational | — | Source → |
| CLL Treatments May Increase Heart Risks | Leukemia | review | — | Source → |
| New Study Compares Heart Risks of CLL Treatments | Leukemia | observational | The incidence of AF/flutter was lower for acalabrutinib compared to ibrutinib [5.8% vs. 11.7%]; the incidence of HTN was also lower in the acalabrutinib cohort [15% vs. 26.3%]. | Source → |
| Zanubrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia: Cost Comparison | Leukemia | phase-3 | Treating 8 patients with zanubrutinib instead of ibrutinib prevented 1 progression or death. | Source → |
| Ibrutinib May Worsen Inflammation in CLL Patients | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.